NeoGenomics RaDaR ST gains expanded Medicare coverage for immunotherapy response monitoring

NEO•2026-08-26

Expanded Medicare coverage for RaDaR ST

NeoGenomics secured expanded Medicare coverage from CMS MolDX for its RaDaR ST MRD assay to monitor immunotherapy response in late-stage solid tumors.

The decision adds a third Medicare-covered indication for RaDaR ST, broadening reimbursement for longitudinal treatment-response monitoring.

NeoGenomics RaDaR ST gains expanded Medicare coverage for immunotherapy response monitoring

Expanded Medicare coverage for RaDaR ST

Related News

Plumas Bancorp EVP, Chief Credit Officer Kevin Craig Kaiser sells 1,200 shares worth $73,800

Metals Royalty signs USD 25 million loan agreement with Macquarie-led lenders

Future FinTech Group announces 1-for-4 reverse stock split

PrimeEnergy Resources director Clint Hurt sells 9,000 common shares worth $1.82 million

Strategy director Jarrod M. Patten disposes of Strategy common shares worth $345,914.50